Partnership to utilize AI for early detection of Alzheimer’s disease, related dementias

A neuroscience company and an emerging artificial intelligence technology firm have announced a partnership that aims to boost access to routine brain care and to facilitate early detection of Alzheimer’s disease and related dementias.

Cognivue Inc. will collaborate with DigiCARE Realized to utilize two complementary technologies: the latter’s AI, which analyzes electronic health records to locate individuals who may have undiagnosed, early-stage ADRD with a high degree of accuracy; the former’s Cognivue Clarity technology, which can evaluate six cognitive domains in 10 minutes to scan for early signs of impairment, according to a release from Cognivue.

“Our DigiCARE Realized partnership will offer health systems a comprehensive method to bring better brain health to their communities, with an innovative means to detect and therefore treat Alzheimer’s disease and other cognitive illnesses earlier,” Cognivue CEO Tom O’Neill said in the release. “It also opens the door for follow-on advancements and flexible models that could improve patient outcomes in all populations.”

Current early detection approaches for AD and other cognitive diseases are neither standardized nor scalable for most underserved urban and rural communities. Per the release, data published in the Journal of the American Geriatrics Society speculated that almost 50% of AD and other cognitive impairment cases go undiagnosed, while confirmation for those who receive a diagnosis can take up to 5 years in a clinical setting.

“Early detection is the first step to a timely and accurate Alzheimer’s diagnosis,” DigiCARE Realized CEO Brittany Cassin said in the release. “The time is now to implement modernized approaches to manage cognitive health for all.”